Novartis reports one year results of two-year phase III MERLIN study of Beovu (brolucizumab) vs. aflibercept

Beovu 6mg met primary endpoint of non-inferiority in change in best corrected visual acuity from baseline at 1 year vs. aflibercept 2mg when given every four weeks following loading phase. Overall rate of vision loss (≥15 letters) due to all causes was 4.8% vs. 1.7%, respectively

Source:

Biospace Inc.